Inflammation and Immunology Areas of Interest

Atopic Dermatitis (AD)

Research areas to be considered for Pfizer support include:

• Basic and clinical research to further characterize the various endotypes and phenotypes of patients with AD and their response to AD treatments
• Non-interventional studies (including epidemiological studies) related to disease burden, costs, comorbidities, and unmet need for new AD
• Translational research regarding the role of JAK/STAT pathway in AD and other skin diseases
• Clinical research into the use of JAK-1-inhibitors in AD and other dermatologic inflammatory and non-inflammatory conditions.
• Optimization of healthcare delivery for patients with moderate-severe AD

Out of Scope:

• Use in non-dermatologic conditions

Research areas to be considered for funding include:

• Treatment outcomes in moderate aplastic anemia, including adult and pediatric populations.
• Short‑ and long‑term clinical outcomes following treatment with horse anti‑thymocyte globulin (hATG) and transplantation approaches, including haploidentical transplantation.
• Studies evaluating treatment outcomes with enhanced product traceability, including patient‑level identification of administered product batches, to support safety and real‑world evidence generation.

NOTE: Drug supply will only be considered on a case-by-case basis.

Out of Scope:

• Use of active drug substance for clinical use
• Protocols which include product reformulation or compounding
• Protocols requesting placebo formulations

• Identify biomarkers and other predictors of treatment response (including clinical, endoscopic, ultrasonographic, histologic, genetic, and other markers), as well as disease monitoring tools in Inflammatory Bowel Disease.
• Evaluate the efficacy and safety of advanced combination therapy in patients with Inflammatory Bowel Disease.
• Further elucidate the effect of S1P receptor modulation on safety outcomes, such as vaccine response.
• Evaluate the use of intestinal ultrasound to monitor response to etrasimod treatment in Ulcerative Colitis, including proctitis.
• Assess the efficacy and safety of etrasimod in different Ulcerative Colitis populations, including patients with proctitis, the elderly, adolescents, and in those with other forms of colitis such as microscopic colitis.
• Evaluate the real‑world effectiveness and safety of etrasimod in Ulcerative Colitis assessing its impact on fatigue, sleep, and other patient‑reported outcomes.
• Characterize the role of etrasimod in managing extra‑intestinal manifestations of Ulcerative Colitis.
• Assess the role of etrasimod within the treatment paradigm for Ulcerative Colitis, including use before or after other advanced therapies with different mechanisms of action.
• Explore the role of Etrasimod in early UC management and in mild to moderate UC patients.

Out of Scope:

• Studies that overlap with completed, ongoing and planned research.
• Use in non-IBD conditions.

Research areas to be considered for Pfizer support include:

• Basic and clinical research to further characterize the variety of patients with alopecia areata (AA) or vitiligo and their response to AA or vitiligo treatments
• Non-interventional studies (including epidemiological studies) related to disease burden, costs, comorbidities, unmet needs and pattern of treatments for AA or vitiligo.
• Translational research regarding the role of JAK3 and TEC family kinase pathways in AA, vitiligo, or other skin diseases, as well as their modulation by therapeutic intervention.
• Clinical research to assess the impact on therapeutic efficacy of early or delayed treatment with ritlecitinib in AA or Vitiligo.
• Clinical research into the use of ritlecitinib in other skin diseases.
• Studies evaluating ritlecitinib treatment in diverse patients (ex. skin of color, adolescents…)

Out of Scope:

• Use in non-dermatologic conditions
• Ritlecitinib is only approved for patients with severe AA 12 years and older.
• Pfizer does not have any approved treatments for vitiligo.